SugenTech Inc

SugenTech's capital structure shows a debt-to-equity ratio of 0.2, indicating a conservative leverage profile. The company holds KRW 19.86 billion in cash and equivalents, representing 20.2% of total assets, but is experiencing negative operating cash flow of KRW -14.65 billion and free cash flow of KRW -20.65 billion. The current ratio of 10.65 suggests strong short-term liquidity, but the negative operating income of KRW -25.5 billion and net loss of KRW -23.31 billion indicate significant operational challenges. Profitability metrics are sharply negative, with a return on equity of -30.55% and return on assets of -23.74%, both well below the industry median for medical equipment and diagnostics firms. The company's gross profit margin of 8.61% (KRW 811 million on KRW 9.42 billion revenue) is also below the 12-15% range typical for in-vitro diagnostic firms. Geographically, SugenTech derives the majority of its revenue from domestic Korean markets, with a secondary focus on Indonesia. The company does not disclose revenue by segment, but its product portfolio includes consumer-facing SUREARLY diagnostics and professional INCLIX POCT systems. The lack of segment reporting limits visibility into growth drivers and risk concentrations. The company's revenue of KRW 9.42 billion represents a decline from prior periods, with no clear growth trajectory identified in the outlook. Capital expenditures of KRW -392 million suggest minimal investment in expansion, which may hinder long-term growth potential. The absence of positive revenue or margin trends raises concerns about the company's ability to achieve profitability in the near term. Risk factors include the company's negative operating and net income, which could pressure liquidity if cash burn continues. The risk assessment indicates low dilution risk, but the absence of shares outstanding changes and no recent equity issuance suggests limited near-term dilution pressure. However, the company's negative cash flows and operating losses represent a material risk to long-term viability. Recent filings show no immediate liquidity or dilution flags, but the company's financial statements reveal significant operating losses and negative cash flows. No recent earnings call transcripts or material events were identified that would suggest a turnaround in operations or strategic shifts.